Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Immunomedics Inc patents


Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors


Therapy of small-cell lung cancer (sclc) with a topoisomerase-i inhibiting antibody-drug conjugate (adc) targeting trop-2

The present invention relates to treatment of sclc with therapeutic adcs comprising a drug attached to an anti-trop-2 antibody or antigen-binding antibody fragment. Preferably, the drug is sn-38. ... Immunomedics Inc

Chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. ... Immunomedics Inc

Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies

The present invention concerns compositions and methods of use of anti-hla-dr antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. ... Immunomedics Inc

Antibody-sn-38 immunoconjugates with a cl2a linker

The present invention concerns improved methods and compositions for preparing sn-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the sn-38 is attached to the antibody or antibody fragment using a cl2a linker, with 1-12, more preferably 6-8, alternatively 1-5 sn-38 moieties per antibody or antibody fragment. ... Immunomedics Inc

Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells

Described herein are compositions and methods of use of anti-trop-2 antibodies or antigen-binding fragment thereof to isolate, enrich, detect, diagnose and/or characterize circulating tumor cells (ctcs) from patients with a trop-2 positive cancer. Preferably, the antibody is an rs7, 162-46.2 or mab650 antibody. ... Immunomedics Inc

Rs7 antibodies

This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. ... Immunomedics Inc

Antibody-sn-38 immunoconjugates with a cl2a linker

The present invention concerns improved methods and compositions for preparing sn-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the sn-38 is attached to the antibody or antibody fragment using a cl2a linker, with 1-12, more preferably 6 or less, most preferably 1-5 sn-38 moieties per antibody or antibody fragment. ... Immunomedics Inc

Anti-histone therapy in acute kidney injury

Acute kidney injury (aki) is often associated with damage to remote organs, such as lungs or heart. Aki induces kidney tubular necrosis as well as netosis, programmed neutrophil death leading to neutrophil extracellular traps (nets). ... Immunomedics Inc

Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1

The present invention concerns compositions and methods of use of anti-pd-1 antibodies comprising cdr sequences corresponding to seq id no:1 to seq id no:6. Preferably the antibody is a humanized antibody comprising the variable region amino acid sequences of seq id no: 9 and seq id no:10. ... Immunomedics Inc

Chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. ... Immunomedics Inc

Efficacy of anti-hla-dr antibody drug conjugate immu-140 (hl243-cl2a-sn-38) in hla-dr positive cancers

The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an anti-hla-dr antibody or antigen-binding antibody fragment. The immunoconjugate may be administered at a dosage of between 3 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8, 10 or 12 mg/kg. ... Immunomedics Inc

Fusion proteins containing recombinant cytotoxic rnases

Recombinant immunotoxins containing a cytotoxic rnase fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic rnase fused to the n-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. ... Immunomedics Inc

Crosslinking of cd22 by epratuzumab triggers bcr signaling and caspase-dependent apoptosis in hematopoietic cancer cells

Extensive crosslinking of cd22 by plate-immobilized epratuzumab induced intracellular changes in daudi cells similar to ligating b-cell antigen receptor (bcr) with a sufficiently high amount of anti-igm. Either treatment leads to phosphorylation of cd22, cd79a and cd79b, along with their translocation to lipid rafts, both of which were needed to induce caspase-dependent apoptosis. ... Immunomedics Inc

Methods of treating cancer with antibodies that target the insulin-like growth factor type i receptor (igf-1r)

The present invention provides compositions and methods of use of anti-igf-1r antibodies or antibody fragments. Preferably the antibodies bind to igf-1r but not ir; are not agonists for igf-1r; do not block binding of igf-1 or igf-2 to isolated igf-1r, but effectively neutralize activation of igf-1r by igf-1 in intact cells; and block binding of an r1 antibody to igf-1r. ... Immunomedics Inc

10/05/17 / #20170283442

Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules

The present application discloses compositions and methods of synthesis and use of 18f- or 19f-labeled molecules of use in pet, spect and/or mr imaging. Preferably, the 18f or 19f is conjugated to a targeting molecule by formation of a complex with a group iiia metal and binding of the complex to a bifunctional chelating agent, which may then be directly or indirectly attached to the targeting molecule. ... Immunomedics Inc

10/05/17 / #20170281791

Anti-trop-2 antibody-drug conjugates and uses thereof

Described herein are compositions and methods of use of antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody or antigen-binding fragment thereof, conjugated to one or more cytotoxic drugs. Preferably, the antibody is an rs7, 162-46.2 or mab650 antibody. ... Immunomedics Inc

09/28/17 / #20170275363

Humanized anti-cd22 antibody

Disclosed are humanized rfb4 antibodies or antigen-binding fragments thereof. Therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. ... Immunomedics Inc

09/28/17 / #20170274093

Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer

The present invention relates to combination therapy with drugs, such as microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or pi3k inhibitors, with antibodies or immunoconjugates against hla-dr or trop-2. Where immunoconjugates are used, they preferably incorporate sn-38 or pro-2pdox. ... Immunomedics Inc

09/28/17 / #20170274079

Rs7 antibodies

This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. ... Immunomedics Inc

09/21/17 / #20170266316

Immunoconjugates with an intracellularly-cleavable linkage

The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.. . ... Immunomedics Inc

09/21/17 / #20170266310

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly. ... Immunomedics Inc

09/21/17 / #20170266281

Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease

Disclosed are methods, compositions and uses of concentrated formulations of anti-cd74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (sle). ... Immunomedics Inc

09/14/17 / #20170260287

Stable compositions of high-concentration allotype-selected antibodies for small-volume administration

Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2. ... Immunomedics Inc

08/31/17 / #20170246291

T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines

The present invention concerns methods and compositions for treatment of hiv infection using a t20 expression vector, such as that shown in seq id no:1 or seq id no:3. The t20 expression vector may be used in a variety of therapeutic applications, such as ex vivo transfection of dendritic cells to induce a host immune response to hiv, localized transfection in vivo in a gene therapy approach to provide longer term delivery of t20, or in vitro production of t20 peptide. ... Immunomedics Inc

08/24/17 / #20170239368

Immunoconjugates with an intracellularly-cleavable linkage

The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.. . ... Immunomedics Inc

08/10/17 / #20170226205

Therapeutic use of anti-cd22 antibodies for inducing trogocytosis

Disclosed are methods and compositions of anti-b cell antibodies, preferably anti-cd22 antibodies, for diagnosis, prognosis and therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-b cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention. ... Immunomedics Inc

08/10/17 / #20170224837

Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers

The present invention relates to therapeutic adcs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is sn-38. ... Immunomedics Inc

08/03/17 / #20170218059

Methods for treating thrombosis using chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. ... Immunomedics Inc

08/03/17 / #20170216447

Combination therapy with anti-hla-dr antibodies and kinase inhibitors in hematopoietic cancers

The present invention relates to combination therapy with drugs, such as bruton's tyrosine kinase inhibitors or pi3k inhibitors, with antibodies or adcs against hla-dr. Where adcs are used, they preferably incorporate sn-38 or pro-2pdox. ... Immunomedics Inc

07/27/17 / #20170209594

Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors

The present invention relates to combination therapy with adcs against a tumor-associated antigen, such as trop-2, and drugs, such as microtubule inhibitors and/or parp inhibitors. Where adcs are used, they preferably incorporate sn-38 or another drug that induces dna strand breaks. ... Immunomedics Inc

06/22/17 / #20170173167

Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments

The present invention concerns methods and compositions for treatment of hiv infection in a subject. The compositions may comprise a targeting molecule against an hiv antigen, such as an anti-hiv antibody or antibody fragment. ... Immunomedics Inc

06/15/17 / #20170165370

Antibody-sn-38 immunoconjugates with a cl2a linker

The present invention concerns improved methods and compositions for preparing sn-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the sn-38 is attached to the antibody or antibody fragment using a cl2a linker, with 1-12, more preferably 6 or less, most preferably 1-5 sn-38 moieties per antibody or antibody fragment. ... Immunomedics Inc

06/01/17 / #20170152315

Anti-cd19 antibodies

The present invention provides humanized, chimeric and human anti-cd19 antibodies, anti-cd19 antibody fusion proteins, and fragments thereof that bind to a human b cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various b-cell disorders, including b-cell malignancies and autoimmune diseases. ... Immunomedics Inc

06/01/17 / #20170151356

Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases

Disclosed herein are compositions and methods of use comprising combinations of anti-cd22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-cd22 antibody or may be separately administered, either before, simultaneously with or after the anti-cd22 antibody. ... Immunomedics Inc

05/18/17 / #20170137534

Anti-pancreatic cancer antibodies

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human pam4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. ... Immunomedics Inc

04/27/17 / #20170114126

Anti-histone therapy for vascular necrosis in severe glomerulonephritis

Severe glomerulonephritis involves cell necrosis as well as netosis, programmed neutrophil death leading to expulsion of nuclear chromatin and neutrophil extracellular traps (nets). Histones released by neutrophils undergoing netosis killed glomerular endothelial cells, podocytes, and parietal epithelial cells. ... Immunomedics Inc

03/30/17 / #20170088619

Antibody-based depletion of antigen-presenting cells and dendritic cells

Disclosed herein are methods and compositions comprising anti-cd74 and/or anti-hla-dr antibodies for treatment of gvhd and other immune dysfunction diseases. In preferred embodiments, the anti-cd74 and/or anti-hla-dr antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. ... Immunomedics Inc

03/09/17 / #20170066828

Humanized anti-hla-dr antibodies

The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc. ... Immunomedics Inc

02/09/17 / #20170035908

Detection of early-stage pancreatic adenocarcinoma

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human pam4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. ... Immunomedics Inc

02/02/17 / #20170028081

Immunoconjugates with an intracellularly-cleavable linkage

The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.. . ... Immunomedics Inc

01/19/17 / #20170014527

Antibody-drug conjugates and uses thereof

The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to trop-2 or ceacam5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. ... Immunomedics Inc

01/19/17 / #20170014403

Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity

The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. ... Immunomedics Inc

01/12/17 / #20170007727

Methods of imaging with ga-68 labeled molecules

The present application discloses compositions and methods of use of 68ga labeled molecules. Preferably, the 68ga is attached to a peptide targetable construct and is used in a pretargeting technique with a bispecific antibody (bsab). ... Immunomedics Inc

01/05/17 / #20170000896

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly. ... Immunomedics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###